Literature DB >> 22318486

[Amyloidosis of the heart].

A V Kristen1, C Röcken.   

Abstract

Amyloidosis is a heterogeneous group of diseases characterized by the pathological deposition of autologous proteins in an antiparallel β-sheet confirmation forming non-branching linear fibrils of indefinite length and an approximate diameter of 10-12 nm. Cardiac amyloidosis is caused by deposits in the heart and may lead to cardiac arrhythmia and low output failure. Following the diagnosis, classification of the amyloid protein and evaluation of further organ involvement is mandatory. Treatment approaches are based on reduction of the production of amyloid precursor proteins. Standard heart failure treatment is usually not well tolerated and the underlying disease remains unaffected. Cardiac amyloidosis, especially of the light chain type, is associated with a poor outcome. The clinical picture is uncharacteristic, therefore correct diagnosis of cardiac amyloidosis is often delayed in many patients. Combination of clinical symptoms of different organ systems should alert the physician to the diagnosis of amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318486     DOI: 10.1007/s00292-011-1558-4

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  38 in total

1.  Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence.

Authors:  R P Linke
Journal:  Virchows Arch       Date:  2000-05       Impact factor: 4.064

Review 2.  Diagnosis and management of the cardiac amyloidoses.

Authors:  Rodney H Falk
Journal:  Circulation       Date:  2005-09-27       Impact factor: 29.690

3.  Immunohistochemical classification of amyloid in surgical pathology revisited.

Authors:  Anja Kebbel; Christoph Röcken
Journal:  Am J Surg Pathol       Date:  2006-06       Impact factor: 6.394

Review 4.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

Review 5.  Amyloidosis: is a cure possible?

Authors:  G Merlini; G Palladini
Journal:  Ann Oncol       Date:  2008-06       Impact factor: 32.976

6.  Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?

Authors:  Werner Hunstein
Journal:  Blood       Date:  2007-09-15       Impact factor: 22.113

7.  Nomenclature of amyloid and amyloidosis. WHO-IUIS Nomenclature Sub-Committee.

Authors: 
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

8.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

9.  Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.

Authors:  Gustaf Herlenius; Henryk E Wilczek; Marie Larsson; Bo-Göran Ericzon
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

10.  Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

Authors:  Arnt V Kristen; Thomas J Dengler; Ute Hegenbart; Stefan O Schonland; Hartmut Goldschmidt; Falk-Udo Sack; Frederik Voss; Rüdiger Becker; Hugo A Katus; Alexander Bauer
Journal:  Heart Rhythm       Date:  2007-10-09       Impact factor: 6.343

View more
  1 in total

1.  [What gnaws at the heart and gets on the nerves].

Authors:  Arnt V Kristen
Journal:  Internist (Berl)       Date:  2018-11       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.